Discussion of prevalence and management of discomfort when swallowing pills: Orodispersible tablets expand treatment options in patients with depression

Therapeutic Delivery

Volumn 2, Issue 5, 2011, Pages 611-622

  Llorca, Pierre Michel ^a  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; FLUOXETINE; LANSOPRAZOLE; MIRTAZAPINE; OLANZAPINE; SELEGILINE; SERTRALINE; VOGLIBOSE; ZOLMITRIPTAN;

ANXIETY; COPING BEHAVIOR; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DYSPHAGIA; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; GENERAL PRACTICE; HUMAN; MENTAL HEALTH; MIGRAINE; MORPHOLOGY; ORODISPERSIBLE TABLET; OROPHARYNX; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PILL; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SWALLOWING; TABLET; WEIGHT REDUCTION;

EID: 79956063248     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.32     Document Type: Review

References (72)

1. Atkinson M, Kramer P, Wyman SM, Ingelfinger FJ. The dynamics of swallowing. I. Normal pharyngeal mechanisms. J. Clin. Invest. 36(4), 581-588 (1957).
2. Spieker MR. Evaluating dysphagia. Am. Fam. Physician 61(12), 3639-3648 (2000).
3. Paterson WG. Dysphagia in the elderly. Can. Fam. Physician 42, 925-932 (1996). (Pubitemid 126699791)
4. Cabre M, Serra-Prat M, Palomera E, Almirall J, Pallares R, Clavé P. Prevalence and prognostic implications of dysphagia in elderly patients with pneumonia. Age Ageing 39(1), 39-45 (2010).
5. Clavé P, Terré R, de Kraa M, Serra M. Approaching oropharyngeal dysphagia. Rev. Esp. Enferm. Dig. 96(2), 119-131 (2004). (Pubitemid 38404361)
6. Miller N, Allcock L, Hildreth AJ, Jones D, Noble E, Burn DJ. Swallowing problems in Parkinson disease: Frequency and clinical correlates. J. Neurol. Neurosurg. Psychiatry 80(9), 1047-1049 (2009).
7. Morris H. Managing dysphagia in older people. Primary Health Care 16(6), 34-36 (2006).
8. Chen CL, Orr WC. Comparison of esophageal motility in patients with solid dysphagia and mixed dysphagia. Dysphagia 20(4), 261-265 (2005).
9. Eslick GD, Talley NJ. Dysphagia: Epidemiology, risk factors and impact on quality of life - a population-based study. Aliment. Pharmacol. Ther. 27(10), 971-979 (2008). (Pubitemid 351537650)
10. Chiocca JC, Olmos JA, Salis GB, Soifer LO, Higa R, Marcolongo M. Prevalence, clinical spectrum and atypical symptoms of gastro-oesophageal reflux in Argentina: A nationwide population-based study. Aliment. Pharmacol. Ther. 22(4), 331-342 (2005). (Pubitemid 41207463)
11. Loeb M, McGreer A, McArthur M, Walter S, Simor AE. Risk factors for pneumonia and other lower respiratory tract infections in elderly residents of long-term care facilities. Arch. Intern. Med. 159(17), 2058-2064 (1999). (Pubitemid 29453594)
12. Vergis EN, Brenner C, Wagener M, Muder RR. Pneumonia in long-term care: A prospective case-control study of risk factors and impact on survival. Arch. Intern. Med. 161(19), 2378-2381 (2001). (Pubitemid 32980137)
13. Roy N, Stemple J, Merrill RM, Thomas L. Dysphagia in the elderly: Preliminary evidence of prevalence, risk factors, and socioemotional effects. Ann. Otol. Rhinol. Laryngol. 116(1), 858-865 (2007). (Pubitemid 350174847)
14. Chen PH, Golub JS, Hapner ER, Johns MM 3rd. Prevalence of perceived dysphagia and quality-of-life impairment in a geriatric population. Dysphagia 24(1), 1-6 (2009).
15. Lindgren S, Janzon L. Prevalence of swallowing complaints and clinical findings among 50-79-year-old men and women in an urban population. Dysphagia 6(4), 187-192 (1991).
16. Channer KS, Virjee JP. The effect of formulation on oesophageal transit. J. Pharm. Pharmacol. 37(2), 126-129 (1985). (Pubitemid 15162013)
17. Gallo SH, McClave SA, Makk LJ, Looney SW. Standardization of clinical criteria required for the use of the 12.5 millimeter barium tablet in evaluating esophageal luminal patency. Gastrointest. Endosc. 44(2), 181-184 (1996). (Pubitemid 26271916)
18. Stein HJ, Schwizer W, DeMeester TR, Albertucci M, Bonavina L, Spires-Williams KJ. Foreign body entrapment in the esophagus of health subjects - a manometric and scintigraphic study. Dysphagia 7(4), 220-25 (1992).
19. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J. Pharm. Pharmacol. 50(4), 375-382 (1998). (Pubitemid 28197414)
20. Andersen O, Zweidorff OK, Hjelde T, Rødland EA. Problems when swallowing tablets. A questionnaire study from general practice [Article in Norwegian]. Tidsskr. Nor. Laegeforen. 115(8), 947-949 (1995).
21. Hansen DL, Tulinius D, Hansen EH. Adolescents' struggles with swallowing tablets: Barriers, strategies and learning. Pharm. World Sci. 30(1), 65-69 (2008). (Pubitemid 350172649)
22. Gilbody JS. Errors of deglutition - real and imagined; or, don't forget the psyche. J. Laryngol. Otol. 105(10), 807-811 (1991). One of very few papers to discuss swallowing problems related to psychological issues.
23. Schwartzberg LS. Chemotherapy-induced nausea and vomiting: Clinician and patient perspectives. J. Support. Oncol. 5(2), 5-12 (2007). (Pubitemid 46344212)
24. Jaspersen D. Drug-induced oesophageal disorders: Pathogenesis, incidence, prevention and management. Drug. Saf. 22(3), 237-249 (2000). (Pubitemid 30157584)
25. Quinzler R, Gasse C, Schneider A, Kaufmann-Kolle P, Szecsenyi J, Haefeli WE. The frequency of inappropriate tablet splitting in primary care. Eur. J. Clin. Pharmacol. 62(12), 1065-1073 (2006). (Pubitemid 44786499)
26. Wright D. Medication administration in nursing homes. Nurs. Stand. 16(42), 33-38 (2002).
27. Verrue C, Mehuys E, Boussery K, Remon JP, Petrovic M. Tablet splitting: A common yet not so innocent practice. J. Adv. Nurs. 67(1), 26-32 (2011).
28. Karch AM, Karch FE. A hard pill to swallow. Am. J. Nurs. 100(4), 25 (2000).
29. Charatan F. Time-release analgesic causes fatal overdoses in United States. West. J. Med. 175(2), 82 (2001).
30. Freeman H. Crushing blow. Daily Mirror, 17 April (2003).
31. Glustein J. To crush or not to crush: Administering solid medication to the elderly patient. Perspectives 8(4), 12-13 (1984).
32. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment. Meta-analysis of the effects of anxiety and depression on patient adherence. Arch. Intern. Med. 160(14), 2101-2107 (2000). Elegant study that analyzes the effect of depression on compliance in patients with somatic illness. Compliance is significantly compromised in these patients, highlighting an important unmet need in this patient population. (Pubitemid 30482715)
33. van Schaick EA, Lechat P, Remmerie BM, Ko G, Lasseter KC, Mannaert E. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin. Ther. 25(6), 1687-1699 (2003). (Pubitemid 36801942)
34. Garvie PA, Lensing S, Rai SN. Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV/AIDS. Pediatrics 119(4), e893-e899 (2007). (Pubitemid 46556653)
35. Beck MH, Cataldo M, Slifer KJ, Pulbrook V, Guhman JK. Teaching children with attention deficit hyperactivity disorder (ADHD) and autistic disorder (AD) how to swallow pills. Clin. Pediatr. (Phila.) 44(6), 515-526 (2005). (Pubitemid 40967693)
36. Bhosle M, Benner JS, DeKoven M, Shelton J. Difficult to swallow: Patient preferences for alternative valproate pharmaceutical formulations. Patient Prefer. Adherence 3, 161-171 (2009).
37. Keith S. Advances in psychotropic formulations. Prog. Neuropsychopharmacol. Biol. Psychiatry 30(6), 996-1008 (2006). Comprehensive review describing the use of alternative formulations in patients with psychiatric disorders. Formulations discussed include alternatives to hard tablets as well as extended-release medications to reduce pill burden. (Pubitemid 43949430)
38. Hirani JJ, Rathod DA, Vadalia KR. Orally disintegrating tablets: A review. Trop. J. Pharm. Res. 8(2), 161-172 (2009).
39. Fu Y, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: Developments, technologies, taste-masking and clinical studies. Crit. Rev. Ther. Drug. Carrier. Syst. 21(6), 433-475 (2004). Comprehensive review of the technologies used to develop orodispersible tablet (ODT) medications and the pharmacokinetic advantages of some existing ODT therapies. (Pubitemid 41647575)
40. Nausieda PA, Pfeiffer RF, Tagliati M, Kastenholz KV, DeRoche C, Slevin JT. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease. Clin. Ther. 27(1), 58-63 (2005). (Pubitemid 40342576)
41. Carnaby-Mann G, Crary M. Pill swallowing by adults with dysphagia. Arch. Otolaryngol. Head Neck Surg. 131(11), 970-975 (2005). Important study highlighting the different swallowing physiologies for ODTs and conventional tablets in patients with dysphagia. (Pubitemid 41696391)
42. Dowson AJ, Charlesworth BR. Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet. Int. J. Clin. Pract. 57(7), 573-576 (2003). (Pubitemid 37185068)
43. Shapero G, Dowson A, Lacoste JP, Almqvist P. Improved migraine management in primary care: Results of a patient treatment experience study using zolmitriptan orally disintegrating tablet. Int. J. Clin. Pract. 60(12), 1530-1535 (2006). (Pubitemid 44742147)
44. Demyttenaere K. Risk factors and predictors of compliance in depression. Eur. Neuropsychopharmacol. 13(Suppl. 3), S69-S75 (2003). (Pubitemid 37188777)
45. Neutel JM, Smith DH. Improving patient compliance: A major goal in the management of hypertension. J. Clin. Hypertens. (Greenwich) 5(2), 127-132 (2003). (Pubitemid 36511309)
46. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: A review. Int. J. Clin. Pract. 62(1), 76-87 (2008). (Pubitemid 350294021)
47. Gonzalez JS, Peyrot M, McCarl LA et al. Depression and diabetes treatment nonadherence: A meta-analysis. Diabetes Care 31(12), 2398-2403 (2008).
48. Koh N, Sakamoto S, Chino F. Improvement in medication compliance and glycemic control with voglibose oral disintegrating tablet. Tohoku J. Exp. Med. 216(3), 249-257 (2008).
49. de Argila CM, Ponce J, Marquez E et al. Acceptability of lansoprazole orally disintegrating tablets in patients with gastro-oesophageal reflux disease: ACEPTO study. Clin. Drug Investig. 27(11), 765-770 (2007). (Pubitemid 47529292)
50. Márquez-Contreras E, Gil V, López J et al. Pharmacological compliance and acceptability of lansoprazole orally disintegrating tablets in primary care. Curr. Med. Res. Opin. 24(2), 569-576 (2008). (Pubitemid 351294405)
51. San L, Casillas M, Ciudad A, Gilaberte I. Olanzapine orally disintegrating tablet: A review of efficacy and compliance. CNS Neurosci. Ther. 14(3), 203-214 (2008).
52. Llorca PM. Monitoring patients to improve physical health and treatment outcome. Eur. Neuropsychopharmacol. 18(Suppl. 3), S140-S145 (2008).
53. Benkert O, Szegedi A, Philipp M et al. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: A double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J. Clin. Psychopharmacol. 26(1), 75-78 (2006). (Pubitemid 43167095)
54. Nelson JC, Hollander SB, Betzel J, Smolen P. Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older. Int. J. Geriatr. Psychiatry 21(9), 898-901 (2006). (Pubitemid 44492564)
55. Varia I, Venkataraman S, Hellegers C, Gersing K, Doraiswamy PM. Effect of mirtazapine orally disintegrating tablets on health-related quality of life in elderly depressed patients with comorbid medical disorders: A pilot study. Psychopharmacol. Bull. 40(1), 47-56 (2007).
56. Benkert O, Muller M, Szegedi A. An overview of the clinical efficacy of mirtazapine. Hum. Psychopharmacol. 17(Suppl. 1), S23-S26 (2002). (Pubitemid 34678887)
57. Behnke K, Sogaard J, Martin S et al. Mirtazapine orally disintegrating tablet versus sertraline: A prospective onset of action study. J. Clin. Psychopharmacol. 23(4), 358-364 (2003). Study highlighting the potential pharmacokinetic benefits of ODTs in patients with depression. ODT mirtazapine has a significantly earlier onset of action than sertraline taken as a hard tablet. (Pubitemid 36951177)
58. Delini-Stula A, Van Oers H, Willigenburg A, Oddens B, Shutte AJ, van der Meulen E. Treating depression with different galenical drug formulations: Does it make a difference? The comparison of mirtazapine fast dissolving formulation (FDT) with conventional mirtazapine tablets (CT). Int. J. Psychiatry Clin. Pract. 13(2), 109-116 (2009). Study comparing the use of conventional and ODT mirtazapine by >3500 patients. The study reports that ODTs improve compliance and are preferred by patients compared with conventional tablets.
59. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet 373(9665), 746-758 (2009).
60. Judge R. Patient perspectives on once-weekly fluoxetine. J. Clin. Psychiatry 62(Suppl. 22), 53-57 (2001). (Pubitemid 32937588)
61. Raskind MA. Diagnosis and treatment of depression comorbid with neurologic disorders. Am. J. Med. 121(Suppl. 2), S28-S37 (2008).
62. Schleifer SJ, Macari-Hinson MM. The nature and course of depression following myocardial infarction. Arch. Intern. Med. 149(8), 1785-1789 (1989). (Pubitemid 19200834)
63. Brintzenhofe-Szoc KM, Levin TT, Li Y, Kissane DW, Zabora JR. Mixed anxiety/depression symptoms in a large cancer cohort: Prevalence by cancer type. Psychosomatics 50(4), 383-391 (2009).
64. Burvill PW, Johnson GA, Jamrozik KD et al. Prevalence of depression after stroke: The Perth Community Stroke Study. Br. J. Psychiatry 166(3), 320-327 (1995).
65. Channer KS, Virjee J. Effect of posture and drink volume on the swallowing of capsules. Br. Med. J. 285(6356), 1702 (1982). (Pubitemid 13240491)
66. Selçuk B, Uysal H, Aydogdu I, Akyuz M, Ertekin C. Effect of temperature on electrophysiological parameters of swallowing. J. Rehabil. Res. Dev. 44(3), 373-380 (2007). (Pubitemid 47075809)
67. Nunn T, Williams J. Formulation of medicines for children. Br. J. Clin. Pharmacol. 59(6), 674-676 (2005). (Pubitemid 40835500)
68. Dautzenberg B, Nides M, Kienzler JL, Calleus A. Pharmacokinetics, safety and efficacy from randomised controlled trials of 1 and 2 mg nicotine bitartrate lozenges (Nicotinell). BMC Clin. Pharmacol. 7, 11 (2007).
69. Wonnemann M, Helm I, Stauss-Grabo M et al. Lidocaine 8 mg sore throat lozenges in the treatment of acute pharyngitis. A new therapeutic option investigated in comparison to placebo treatment. Arzneimittelforschung 57(11), 689-697 (2007). (Pubitemid 350239805)
70. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J. Clin. Psychiatry 64(2), 208-214 (2003). (Pubitemid 36268325)
71. Bodkin JA, Siris SG, Bermanzohn PC, Hennen J, Cole JO. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am. J. Psychiatry 162(2), 388-390 (2005). (Pubitemid 40216224)
72. Koelle JS, Dimsdale JE. Antidepressants for the virtually eviscerated patient: Options instead of oral dosing. Psychosom. Med. 60(6), 723-725 (1998). (Pubitemid 28544034)